IL9 and inflammatory bowel disease: To explore whether IL-12/23 neutralization by anti-p40 (ustekinumab) treatment could impact the disturbed distribution of ILC3 and ILC1 in IBD patients, blood and biopsies from, respectively, 85 and 47 patients initiating ustekinumab treatment were prospectively collected.